Home
Series of Journals
Literature
Latest literature
Popular literature
About us
Intro
Organizational structure
Job Responsibilities
Copyright
Contact us
The title
The title
The keywords
The author
Wuhan University
Zhongnan Hospital of Wuhan University
Center for Evidence-Based and Translational Medicine of Wuhan University
Home
Results
The title
The title
The keywords
The author
A total of
14
result was found. Results that relate to
Cost-effectiveness
Alirocumab in the treatment of hypercholesterolemia: a rapid health technology assessment
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(12):1388-1400.
10460 times
2295 times
Jian-Cheng ZHOU
Chun-Mei JI
Wen-Tong FANG
Ying ZOU
Yong-Qing WANG
Yuan-Yuan FU
Alirocumab
Hypercholesterolemia
Safety
Efficacy
Cost-effectiveness
Rapid health technology assessment
Details
Cost-effectiveness analysis of abemaciclib plus fulvestrant in the second-line treatment for HR﹢/HER2﹣ advanced breast cancer
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(11):1259-1266.
7771 times
2256 times
Xi ZHAO
Xi YAN
Ning LI
Chun-Xia HOU
Abemaciclib
Fulvestrant
Hormone receptor-positive breast cancer
Markov model
Cost-effectiveness
analysis
Details
Cost-effectiveness analysis of enzalutamide in the treatment of metastatic prostate cancer
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(3):269-276.
10982 times
2612 times
YANG Lei
WANG Fengling
HUANG Ling
LI Yan
ZHENG Hanrui
ZHENG Lingli
CHEN Li
Enzalutamide
Metastatic prostate cancer
Markov model
Cost-effectiveness
analysis
Details
Ertugliflozin in the treatment of type 2 diabetes mellitus: a rapid health technology assessment
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(7):778-789.
13575 times
2576 times
QIN Fang
WU Kunrong
LIU Chengyu
LIU Daihua
Ertugliflozin
Type 2 diabetes mellitus
Efficacy
Safety
Cost-effectiveness
Rapid health technology assessment
Details
Research progress of equity-informative health economic evaluation
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(8):929-937.
15857 times
2861 times
FANG Nan
HE Xiaoning
WU Jing
Economic evaluation
Equity
Equity-based weighting
Distributional
cost-effectiveness
Extended
cost-effectiveness
analysis
Details
Economic evaluation of multi-station drug dispensing robots for intravenous infusion preparation
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(12):1375-1381.
19346 times
2060 times
SUN Zhihong
ZHAO Shaoliang
ZHOU Furong
LIU Feiyu
WANG Pengcheng
ZOU Shaohua
GUO Chenyu
Multi-station dispensing robot
Pharmacy intravenous admixture services
Dispensing efficiency
Cost-effectiveness
analysis
Economic evaluation
Details
Pharmacoeconomic evaluation of ribociclib plus fulvestrant in second-line treatment of HR+/HER2- advanced breast cancer for postmenopausal women
Published on
Chinese Journal of Pharmacoepidemiology
2025,34(6):612-620.
12588 times
2107 times
JIA Caifeng
WANG Jie
ZHANG Sen
WANG Meiqi
LI Sainan
WANG Mingxia
Ribociclib
Fulvestrant
Advanced breast cancer
Postmenopausal
Pharmacoeconomic evaluation
Cost-effectiveness
analysis
Details
Tirzepatide in the treatment of type 2 diabetes mellitus: a rapid health technology assessment
Published on
Chinese Journal of Pharmacoepidemiology
2025,34(9):1057-1065.
16370 times
2224 times
ZHANG Yunxuan
ZHOU Haifeng
GAO Ningzhou
WU Jianbo
QIAN Cheng
ZHANG Min
GUO Han
SONG Zhongjuan
LIU Xiaoyan
Tirzepatide
Type 2 diabetes mellitus
Rapid health technology assessment
Efficacy
Safety
Cost-effectiveness
Details
Inclisiran in the treatment of dyslipidemia: a rapid health technology assessment
Published on
Chinese Journal of Pharmacoepidemiology
2025,34(10):1198-1205.
8508 times
1642 times
CHEN Lingbin
PAN Weiping
CHEN Zhou
XU Wentan
Inclisiran
Dyslipidemia
Efficacy
Safety
Cost-effectiveness
Rapid health technology assessment
Details
Mepolizumab for refractory chronic rhinosinusitis with nasal polyps: a rapid health technology assessment
Published on
Chinese Journal of Pharmacoepidemiology
2026,35(2):192-199.
6493 times
1096 times
GU Shilong
ZHANG Wenjing
GUO Hao
Mepolizumab
Refractory chronic rhinosinusitis with nasal polyps
Effectiveness
safety
Cost-effectiveness
Details
Evaluation of the pharmacoeconomics of recombinant human thrombopoietin for the treatment of cancer therapy-induced thrombocytopenia
Published on
Chinese Journal of Pharmacoepidemiology
2026,35(4):371-378.
3831 times
991 times
LIANG Hai
XIA Runan
CHEN Huijuan
JIANG Mengyu
LI Fanqin
YANG Miao
MA Jinghe
Recombinant human thrombopoietin
Interleukin-11
Cancer
Thrombocytopenia
Decision tree
Cost-effectiveness
analysis
Details
Cost-effectiveness analysis of fondaparinux compared with low molecular-weight heparin in the treatment of recurrent spontaneous abortion
Published on
Chinese Journal of Pharmacoepidemiology
2026,35(3):281-287.
3791 times
943 times
ZHU Yurong
LI Lanlan
ZHANG Rui
DAI Wei
YANG Weihu
Recurrent spontaneous abortion
Fondaparinux
Low molecular-weight heparin
Cost-effectiveness
analysis
Details
Cost-effectiveness analysis of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment for progressed EGFR-mutant non-small-cell lung cancer
Published on
Chinese Journal of Pharmacoepidemiology
2026,35(5):553-562.
2818 times
580 times
JIN Lijun
ZHANG Lele
HAN Lu
LYU Zhenye
Sacituzumab tirumotecan
Non-small cell lung cancer
EGFR mutation
Quality adiusted life year
Incremental
Cost-effectiveness
ratio
Cost-effectiveness
analysis
Scenaio analysis
Details
Rapid health technology assessment of donanemab in the treatment of Alzheimer's disease
Published on
Chinese Journal of Pharmacoepidemiology
2026,35(7):800-809.
1043 times
308 times
FAN Liming
DENG Tiantian
LAN Haiyue
DONG Yafen
QIU Yan
WANG Jian
Donanemab
Alzheimer's disease
Efficacy
Safety
Cost-effectiveness
Rapid health technology assessment
Details
Wuhan University
Zhongnan Hospital of Wuhan University
Center for Evidence-Based and Translational Medicine of Wuhan University